Business Description
Vertex Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92532F1003
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 13.88 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.18 | |||||
Interest Coverage | 97.68 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 14.23 | |||||
Beneish M-Score | -2.04 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 17.2 | |||||
3-Year EBITDA Growth Rate | 12.3 | |||||
3-Year EPS without NRI Growth Rate | 13.8 | |||||
3-Year FCF Growth Rate | 3.5 | |||||
3-Year Book Growth Rate | 26.8 | |||||
Future 3-5Y EPS without NRI Growth Rate | 12.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 8.83 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 51.28 | |||||
9-Day RSI | 48.45 | |||||
14-Day RSI | 46.61 | |||||
6-1 Month Momentum % | 11.71 | |||||
12-1 Month Momentum % | 32.26 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.99 | |||||
Quick Ratio | 3.78 | |||||
Cash Ratio | 3.16 | |||||
Days Inventory | 175.05 | |||||
Days Sales Outstanding | 56.57 | |||||
Days Payable | 100.11 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.3 | |||||
Shareholder Yield % | 0.72 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 87.21 | |||||
Operating Margin % | 43.65 | |||||
Net Margin % | 36.68 | |||||
FCF Margin % | 33.34 | |||||
ROE % | 23.23 | |||||
ROA % | 17.76 | |||||
ROIC % | 50.94 | |||||
ROC (Joel Greenblatt) % | 305.61 | |||||
ROCE % | 25.82 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 28.62 | |||||
Forward PE Ratio | 24.39 | |||||
PE Ratio without NRI | 25 | |||||
Shiller PE Ratio | 67.85 | |||||
Price-to-Owner-Earnings | 36.59 | |||||
PEG Ratio | 0.6 | |||||
PS Ratio | 10.49 | |||||
PB Ratio | 5.83 | |||||
Price-to-Tangible-Book | 6.54 | |||||
Price-to-Free-Cash-Flow | 31.58 | |||||
Price-to-Operating-Cash-Flow | 29.27 | |||||
EV-to-EBIT | 20.87 | |||||
EV-to-Forward-EBIT | 18.58 | |||||
EV-to-EBITDA | 20.05 | |||||
EV-to-Forward-EBITDA | 17.7 | |||||
EV-to-Revenue | 9.35 | |||||
EV-to-Forward-Revenue | 8.61 | |||||
EV-to-FCF | 28.16 | |||||
Price-to-Projected-FCF | 2.04 | |||||
Price-to-Median-PS-Value | 0.71 | |||||
Price-to-Peter-Lynch-Fair-Value | 1 | |||||
Price-to-Graham-Number | 2.75 | |||||
Price-to-Net-Current-Asset-Value | 11.39 | |||||
Price-to-Net-Cash | 16.88 | |||||
Earnings Yield (Greenblatt) % | 4.79 | |||||
FCF Yield % | 3.19 | |||||
Forward Rate of Return (Yacktman) % | 22.65 |